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OBJECTIVE — To evaluate early stages of atherosclerosis and predisposing factors in type 1
diabeticchildrenandadolescentscomparedwithage-andsex-matchedhealthycontrolsubjects.
RESEARCH DESIGN AND METHODS — All children and adolescents with type 1
diabetes, aged 8–18 years in Health Region South-East in Norway were invited to participate in
thestudy(n800).Atotalof40%(n314)agreedtoparticipateandwerecomparedwith118
age-matched healthy control subjects. Carotid artery intima-media thickness (cIMT) and elas-
ticity were measured using standardized methods.
RESULTS — Meanageofthediabeticpatientswas13.7years,meandiabetesdurationwas5.5
years, and mean A1C was 8.4%; 97% were using intensive insulin treatment, and 60% were
using insulin pumps. Diabetic patients had more frequently elevated cIMT than healthy control
subjects: 19.5% were above the 90th centile of healthy control subjects, and 13.1% were above
the 95th centile (P  0.001). Mean cIMT was higher in diabetic boys than in healthy control
subjects (0.46  0.06 vs. 0.44  0.05 mm, P  0.04) but not signiﬁcantly so in girls. There was
nosigniﬁcantdifferencebetweenthegroupsregardingcarotiddistensibility,compliance,orwall
stress. None of the subjects had atherosclerotic plaque formation. Although within the normal
range, the mean values of systolic blood pressure, total cholesterol, LDL cholesterol, and apoli-
poproteinBweresigniﬁcantlyhigherinthediabeticpatientsthaninthehealthycontrolsubjects.
CONCLUSIONS — Despite short disease duration, intensive insulin treatment, fair glyce-
mic control, and no signs of microvascular complications, children and adolescents with type 1
diabeteshadslightlyincreasedcIMTcomparedwithhealthycontrolsubjects,andthedifferences
were more prominent in boys.




atic atherosclerosis, and cardiovas-
cular morbidity and mortality are
substantially increased in this group of
patients (1–4).
Carotid artery intima-media thick-
ness (cIMT) is a reliable surrogate marker
of generalized atherosclerosis because it
correlates to coronary artery disease and
predicts future cardiovascular events
(5,6).Furthermore,itisrecommendedby
the American Heart Association as a non-
invasive imaging method for detecting
atherosclerosis (6).
Improved blood-glucose control ob-
tained by intensive insulin treatment is
associated with delayed atherosclerosis
development and fewer cardiovascular
events (2,7,8). The Oslo study, a long-
term study of intensive insulin treatment
in childhood-onset type 1 diabetic pa-
tients without symptomatic cardiovascu-
lar disease (CVD), demonstrated that
long-term glycemic control predicted
coronary atherosclerosis, as detected by
coronary intravascular ultrasound
(IVUS), and was correlated to cIMT (2).
Likewise, the Diabetes Control and Com-
plications Trial (DCCT)/Epidemiology of
Diabetes Interventions and Complica-
tions (EDIC) study found that intensive
insulintherapyreducestheprogressionof
atherosclerosis, measured by IMT and
most important the risk of cardiovascular
events compared with conventional
therapy (8,9).
The atherosclerotic process starts in
childhood and proceeds silently over a
long period of time before clinical events
occur (1). How early it starts and how
aggressively it proceeds is, however, not
quiteknown.StudiesoncIMTinchildren
andadolescentswithtype1diabeteshave
yielded conﬂicting results (10–13), and
sofaronlysmallclinic-basedstudieshave
been performed. The present study is a
population-based study in children and
adolescentswhousemodernintensivein-
sulin treatment, the aim of which is to
evaluate early stages of atherosclerosis, its
progression and predisposing factors,
through follow up every 5th year. In this
article, the baseline characteristics of the
patients are presented, as well as the re-
sults from the ﬁrst analysis.
RESEARCH DESIGN AND
METHODS— All children and ado-
lescents with type 1 diabetes in Norway
are treated at the public hospitals and in-
vited to participate in the Norwegian
Childhood Diabetes Registry (NCDR).
The NCDR includes data on new-onset
diabetes since 1973 and annual bench-
markingdatasince2001(14).Allbutone
pediatric department in Norway (n  26)
participated in this registration in 2007,
withanadherencerateofabout85%ofall
eligible patients.
A letter of invitation was sent to all
type1diabeticpatientsaged8–18years
registered in the NCDR from the de-
ﬁned south-east health region in Nor-
way (n  800), which is highly
representative for the whole country,
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The healthy control subjects were
friends (and relatives in a few cases) of
the participating diabetic children. The
examinations were performed in 2006–
2008. Written informed consent was
obtainedfromtheparentsandfrompar-
ticipants older than 12 years of age. The
study protocols were approved by the
RegionalCommitteeforResearchEthics
and the Norwegian Social Science Data
Services.
The clinical data were registered on a
case record form, which in addition to
anthropometric data contained informa-
tion about diabetes duration, smoking
status,bloodpressure,currenthealth,ad-
ditional diseases, and medication, to-
gether with family history (ﬁrst- and
second-degree relatives) of diabetes and
early CVD (heart attack and/or stroke be-
fore age 60 years). The family history was
recorded by interview of the participant
and the parents.
The following information about the
diabetic patients was obtained from the
NCDR: insulin regimen (insulin type and
dose), acute and chronic complications,
urinary microalbumin excretion rate,
A1C values, and pubertal stage. Height,
weight, and waist circumference were
measured using standard techniques. Ar-
terial blood pressure was measured ac-
cording to the National High Blood
Pressure Education Program Working
Group on High Blood Pressure in Chil-
dren and Adolescents (15). For the dia-
betic patients, the pubertal Tanner stage
was obtained from the NCDR, together
with self-rating. For the control subjects,
only the self-rating was performed.
Blood tests
Fasting venous blood samples were taken
in the morning. Serum glucose, creati-
nine, and lipid concentrations were mea-
sured using standard methods. A1C, in
the NCDR and the present study, was de-
termined for all participants by high-
performance liquid chromatography
(Variant; Bio-Rad, Richmond, CA) at the
same central DCCT-standardized labora-
tory at the clinical chemistry department
of Oslo University Hospital, Aker, Oslo,
Norway. The normal reference range was
4.1–6.4  2%, and the intra-assay coef-
ﬁcient of variation was 3%.
Glycemic burden
Annual A1C values were available from
the NCDR since 2001 or from the time of
diagnosis for the majority of the patients.
Mean A1C was calculated from all the
A1Cvaluesavailableforeachpatientfrom
the ﬁrst NCDR registration until the time
of cIMT analysis.
A1 months was calculated using a
modiﬁed version of the formula devel-
oped by Orchard et al. (16). It was calcu-
lated as the sum of months from the
diagnosis of diabetes until the ﬁrst A1C
value registered in the NCDR multiplied
by A1C units above the upper normal ref-
erence value (6.4%) of the ﬁrst registered
value, plus the number of months from
the ﬁrst to second registration multiplied
by A1C units above the upper normal ref-
erence value of the second registered




A standardized protocol and strict quality
control procedures were implemented to
achieve reliable ultrasonic measurements
of cIMT. Two experienced sonographers,
blindedtotheparticipants’diabetesstatus
and risk factor levels, did all the
examinations.
The subjects were studied in the
morning under standardized conditions
(quiet room, comfortable temperature)
with the participant in the fasting state.
Blood pressure was measured under rest-
ing conditions. High-resolution ultra-
sonography was performed with a
Siemens Acuson Sequoia 512 (Siemens
Acuson; Mountain View, CA) ultrasound
scanner equipped with a linear array 14-
MHz transducer.
The participants were examined in
the supine position with the head
turnedslightlytobothsides.Afteriden-
tifying the bulb, longitudinal images
of the common carotid artery (CCA)
were obtained by combined B-mode
and color Doppler. The scan was fo-
cusedonthefarwall,andtheresolution
box was used to magnify the far wall
segment 10–20 mm proximal of the ca-
rotid bulb, where all measurements
were done. Several images were ac-
quired by using an anterior oblique an-
gle (30° from midline) and lateral (100°
from midline) (17). The IMT of the far
wall was measured during end diastole
(R-wave of the electrocardiogram).
Threescansonbothsideswereselected,
and nine (3  3) measurements of max-
imum far wall IMT on both sides were
averaged; thus, the conclusive mean
IMT of each patient was calculated from
a total of 18 measurements. The CCA
and the carotid bulb region were also
scanned for the presence of atheroscle-
rotic plaques, deﬁned as a distinct area
of the vessel protruding from 50% of
the adjacent parts of the intima-media
layer (18). All scans were digitally
stored on the internal hard disk for sub-
sequent ofﬂine analysis. One experi-
enced reader (K.H.S.), blinded to the
subjects’ clinical details, performed all
measurements. Carotid elastic behavior
was measured from the maximal end-
diastolic interadventitial lumen diameter at
end-diastole (R-wave of the electrocardio-
gram) and end-systole. Two measurements
each of diastolic and systolic diameters on
both sides were averaged. The diameter
change was calculated as the difference be-
tween the systolic and diastolic averages.
Characterization of the carotid ar-
teries’ elastic behavior was performed
through distensibility and compliance,
deﬁned as the relative (V/V) and abso-
lute (V) change in carotid arterial vol-
ume (V) for a change in pulse pressure
(p), respectively. Distensibilty reﬂects
the mechanical load of the artery wall,
and compliance reﬂects the ability to
store volume (19). Both are generally
expressed as changes in lumen cross-
sectional area (A) during the cardiac cy-
cle. The expression for distensibility
coefﬁcient (DC) in terms of end-
diastolic diameter (d) and the change in
diameter (d) from diastole to systole,
assuming a circular lumen cross-




2}/p. Similarly, the com-
pliance coefﬁcient (CC) can be rewrit-
ten as: CC  A/p  {	[(d  d)
2 
d
2]}/4p. In addition, wall stress can be
calculated by the Yong modulus, E,
which is the ratio of stress and circum-
ferential strain in the vessel wall (19). E
is related to DC as (assuming h  IMT):
E  (d/h)/DC.
A total of 12 subjects presented twice
within 8 weeks for the determination of
intra- and intersonographer variability,
and the IMT was measured without
knowledge of the previous values. For
IMT measurements the between-
sonographer intraclass correlation coefﬁ-
cient (ICC) for mean IMT was 1.0 (95%
CI0.997–1.000).Thewithin-subjectICC
was 0.99 (0.977–0.999) for the ﬁrst
sonographer and 0.96 (0.790–0.994) for
the second sonographer.
Statistical analysis
Demographic and clinical data are pre-
sented as means  SD or proportions.
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between males and females were tested
with the Student t test for normally
distributed data and the Mann-Whitney
U test for non-normally distributed data.
The 

2 test for contingency tables with
differentdegreesoffreedomwasobtained
to detect associations between categorical
independent variables. Adjustment for
multipleconfoundingwasdoneusinglin-
ear regression analysis with a manual
backward procedure.
Multivariate analyses were pre-
ceded by estimation of the correlation
between potential confounders. A sig-
niﬁcance level of 5% was used. All sta-
tisticalanalysiswasdoneusingtheSPSS
software package for Windows, version
15.0 (SPSS, Chicago, IL).
ElevatedvaluesoftheIMTmeasure-
ments were deﬁned as above the 90th
and 95th centile of the healthy control
subjects.
RESULTS— The present study in-
volved 314 diabetic patients (participa-
tion rate about 40%) and 118 healthy
control subjects from a geographically
deﬁned region. The diabetic patients in
this study were compared with the dia-
betic patients in the rest of the country
as registered in the NCDR. Data from
the NCDR in 2007 was used for com-
parison (data not shown). The diabetic
patients in this study were found to be
representativeofdiabeticpatientsinthe
whole country, and the recruitment
procedure makes this study a popula-
tion-based study. A1C in the diabetic
patients in this study was similar to that
in the rest of the country (8.43 vs.
8.49%). The diabetic patients in this
study were older than the rest of the
diabeticchildreninthecountry(13.3
2.7 vs. 12.5  3.8 years; P  0.001),
had slightly longer diabetes duration
(5.1 3.3 vs. 5.0  3.9 years; P 
0.04), and had higher BMI (20.6  3.5
vs. 20.0  3.8 kg/m
2; P  0.04). How-
ever, only children older than 8 years of
age were included in the present study,
and all other patients registered in the
NCDR were used for comparison. Sig-
niﬁcantly more participants in the
present study were using intensive in-
sulin treatment (97 vs. 95%; P  0.01),
and more were using insulin pumps
(60vs.48%;P  0.001),thanintherest
of the diabetic patients in the country.
Otherwise the groups were similar (P 
0.05), for instance regarding blood
pressure, lipid status, pubertal stage,
and family history of early CVD and
type 2 diabetes.
The characteristics of the participants
inthepresentstudyareshowninTable1.
The groups (diabetic patients and healthy
control subjects) were similar regarding
sex, age, and pubertal stage. However, a
signiﬁcant difference was observed be-
tween the groups regarding height,
weight, BMI, and waist circumference,
with higher values among the diabetic
subjects for all parameters. In the diabetic
group as a whole, the mean values of sys-
tolic blood pressure, total cholesterol,
LDL cholesterol, and apolipoprotein B
(ApoB) were signiﬁcantly higher than in
the control subjects, although within the
normal range. However, the apolipopro-
tein A1 (ApoA1) values and HDL levels
were also higher in the diabetic group
than in control subjects, making the
groups similar regarding total-to-HDL
cholesterol ration and ApoB-to-ApoA1
ratio (Table 1). There was no difference
between the groups regarding family his-
tory of early CVD and/or type 2 diabetes
(data not shown).
All but 33 subjects (11%) with diabe-
teshadurinaryalbuminexcretionratesin
the normoalbuminuric range. The 33
subjects had only modest microalbumin-
uria, and none had persistent microalbu-
minuria. None of the patients with
diabetes had evidence of microvascular
complications, such as retinopathy, clini-
cal neuropathy, or overt nephropathy.
There was no difference between diabetic
patients and control subjects regarding
mean values of urinary albumin-to-
creatinine ratio (Table 1).
More diabetic patients had elevated
cIMT values; 19.5% were above the 90th
centile and 13.1% above the 95th centile
of the healthy control subjects for IMT
values (P  0.001). Although these ﬁnd-
ings were more pronounced among the
males, the same tendency was observed
among the females as well (data not
shown). Regarding the parameters of ca-
rotid artery elasticity (DC, CC, and DS),
the proportion of diabetic patients above
the 90th or 95th centile was not signiﬁ-
cantly elevated compared with the
healthy control subjects (Table 2).
The boys had higher mean cIMT
than the girls (0.46  0.06 vs. 0.44 
0.05 mm; P  0.008). The diabetic pa-
tients had a slightly higher mean cIMT
than the control subjects (0.45 vs. 0.44
mm) (Table 3), but the difference was
not statistically signiﬁcant, even after
adjustingformultipleconfounders.The
mean cIMT was, however, signiﬁcantly
higher among diabetic boys than age-
matched healthy control subjects
(0.46  0.06 vs. 0.44  0.05 mm; P 
0.04) but not among diabetic girls. A
signiﬁcant difference between patients
and control subjects was not found for
mean values of CC (9.95 vs. 9.90), DC
(0.35 vs. 0.36), or carotid wall stress
(0.13 in both groups). No plaque for-
mation was observed in any of the chil-
dren studied.
AdirectassociationbetweenIMTand
age was not found. However, an increase
in IMT with age was shown through the
ﬁrst three age quartiles, but no further in-
crease was found in the fourth age
quartile.
AnassociationbetweenIMTandA1C
or lipid levels was not found in the group
as a whole, or in the diabetic patient
group only, or in either sex. The same is
trueregardingfamilyhistoryofearlyCVD
and/or type 2 diabetes in the family.
In the diabetic patients, there was no
associationbetweenIMTanddiabetesdu-
ration or glycemic burden (mean A1C or
calculated A1 months). However, there
was an association between IMT and age
of diabetes onset (P  0.045).
CONCLUSIONS — The diabetic
subjects in this study showed signs of
early atherosclerosis by having elevated
cIMT two to three times more frequently
than healthy control subjects, the differ-
ence being most prominent in the boys.
cIMT is found to be well suitable as a
surrogate end point in clinical studies
(1,5,6). It correlates well with cardiovas-
cularriskfactorsandcoronaryatheroscle-
rosis (1) and is an independent predictor
of future cardiovascular events (5). It also
shows a good correlation with invasive
examinations such as coronary angiogra-
phy and IVUS (1,7). cIMT is a well-
validated and safe examination with high
reproducibility that can be repeatedly
performed with no adverse effect on the
patient. However, this method relies on
the technician, and procedures must be
standardized to avoid inaccurate estima-
tionofcIMTmeasurements.Ifsuchissues
are resolved, this method can be appro-
priate for identifying and possibly moni-
toring subjects at an increased risk of
future vascular events (1,5,6).
Studies on cIMT in children and ad-
olescents have yielded conﬂicting results;
some studies show increased cIMT in
diabetic patients, whereas others do not
(10–13,20,21). The different results may
Margeirsdottir and Associates
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niques used, as well as different popula-
tions. The most referred study on the
subject, conducted by Ja ¨rvisalo and col-
leagues (11,20), found signiﬁcantly ele-
vated IMT in both the aorta and carotid
artery of diabetic patients compared with
control subjects. The difference was,
however, greater in the aorta (20), which
was not examined in this study. In con-
trast to our study, which is a population-
based study with a large number of
patients, most other studies were clinic-
based studies with a small number of par-
ticipants and generally did not include
information about insulin regime.
Though the children and adolescents in
thisstudyhadonlyslightlyelevatedmean
cIMT,withsigniﬁcantchangesintheboys
only, a signiﬁcantly higher number of the
diabeticpatientshadcIMTabovethenor-
mal level, indicating more atherosclerosis
development in the diabetic group com-
pared with the control group.
The sex difference in cIMT observed
in our study is in concordance with the
general population of children and ado-
lescents whereby atherosclerosis and
CVD are more common among males
than females (22). Similarly, Peppa-
Patridiou et al. (21) found greater IMT
values in male type 1 diabetic adolescents
than in male control subjects (0.52 
0.09 and 0.45  0.06, respectively; P 
0.015). Some study results indicate that
the sex beneﬁt on atherosclerosis and
Table 2—Diabetic patients above 90th and
95th percentile values of healthy control sub-
jects for cIMT, carotid artery elasticity, and







cIMT 41 (14.0) 61 (19.4)
DC 21 (6.7) 30 (9.6)
CC 22 (7.0) 43 (13.7)
Yong modulus 30 (9.6) 347 (15.0)
SBP 18 (5.8) 37 (12.0)
DBP 23 (7.5) 45 (14.6)
Total cholesterol 33 (10.7) 50 (16.3)
LDL cholesterol 30 (9.8) 63 (20.5)
HDL cholesterol 22 (7.0) 45 (14.7)
Data are n (%).
Table 1—Clinical characteristics and metabolic and anthropometric data of the participants
Total Male Female
Diabetes Control P Diabetes Control P Diabetes Control P
n 314 118 155 53 159 65
Age (years) 13.8  2.8 13.2  2.6 0.73 13.4  2.80 13.3  2.44 0.7 14.1  2.85 13.2  2.7 0.03
Duration of diabetes (years) 5.5  3.4 5.6  3.4 0 5.4  3.4 0
Pubertal stage (Tanner) 3.2  1.5 2.9  1.4 0.36 2.9  1.6 2.8  1.4 0.52 3.5  1.4 3.0  1.4 0.15
Height (cm) 160.4  14.4 156.8  13.6 0.02 160.6  14.7 157.6  16.2 0.24 160.3  12.3 156.2  12.6 0.02
Weight (kg) 54.9  16.7 47.9  13.4 0.001 53.3  17.4 46.9  12.1 0.004 56.5  14.4 48.7  14.4 0.001
BMI (kg/m
2) 20.9  3.939 19.1  0.3 0.001 20.1  3.6 18.6  2.3 0.001 21.6  4.1 19.5  3.6 0.001
Waist circumference (cm) 71.2  10.0 66.7  6.7 0.001 70.3  10.0 65.9  6.5 0.001 72.1  9.9 67.4  6.8 0.001
SBP (mmHg) 101.0  10.1 98.0  10.2 0.006 101.0  9.8 96.8  10.7 0.01 101.0  10.3 99.0  9.6 0.18
DBP (mmHg) 60.5  8.3 58.5  7.8 0.22 59.6  8.4 58.1  9.2 0.29 61.5  8.2 58.8  6.2 0.009
Smoking 11 (3.5) 2 (2) 0.53 2 (1.3) 0 (0) 1 9 (5.7) 2 (3.1) 0.52
Urinary albumin-to-
creatinine ratio 1.4  3.7 1.3  1.9 0.72 1.8  4.9 1.1  1.7 0.32 1.0  1.1 1.5  2.0 0.11
S-creatinine (mol/l) 53.1  10.3 54.5  10.1 0.23 53.7  10.8 55.5  10.2 0.3 52.5  9.7 53.6  9.9 0.43
Fasting blood glucose
(mmol/l) 10.9  4.8 4.9  0.4 0.001 10.1  5.1 4.9  0.4 0.001 10.8  4.5 4.8  0.5 0.001
A1C (%) 8.4  1.3 5.3  0.5 0.001 8.3  1.2 5.3  0.6 0.001 8.4  1.3 5.3  0.4 0.001
Mean A1C (%) 8.2  1.0 8.1  1.0 8.2  1.0
A1 months* 119  104.1 120.8  107.1 117.9  101.5
Total cholesterol (mmol/l) 4.6  0.9 4.3  0.8 0.002 4.6  0.8 4.3  0.8 0.11 4.7  0.8 4.4  0.7 0.004
HDL cholesterol (mmol/l) 1.8  0.4 1.70  0.4 0.07 1.8  0.4 1.7  0.5 0.8 1.8  0.4 1.7  0.3 0.20
LDL cholesterol (mmol/l) 2.5  0.7 2.3  0.7 0.028 2.5  0.7 2.2  0.7 0.13 2.5  0.7 2.4  0.7 0.09
LDL-to-HDL cholesterol
ratio 1.5  0.6 1.5  0.7 0.7 1.5  0.7 1.4  0.7 0.48 1.5 0.6 1.5  0.6 0.99
Total-to-LDL cholesterol
ratio 2.7  0.8 2.7  0.8 0.7 2.7  0.8 2.6  0.8 0.48 2.7  0.7 2.7  0.7 0.89
Triglycerides (mmol/l) 0.8  0.4 0.7  0.4 0.32 0.8  0.4 0.7  04 0.35 0.8  0.4 0.8  0.4 0.51
ApoB (g/l) 0.7  0.2 0.7  0.2 0.001 0.7  0.2 0.7  0.2 0.02 0.8  0.2 0.7  0.2 0.006
ApoA1 (g/l) 1.6  0.3 1.5  0.3 0.003 1.6  0.3 1.5  0.3 0.48 1.6  0.3 1.4  0.3 0.001
ApoB-to-ApoA1 ratio 0.5  0.2 0.5  0.3 0.75 0.5  1.6 0.5  0.2 0.37 0.5  0.1 0.5  0.3 0.44
Insulin dose (U/kg/day) 0.9  0.4 0.9  0.3 0.9  0.4
Injections per day
1–2 1 (0.4) 0 1 (0.6)
3 6 (2.4) 3 (2.5) 3 (2.3)
4 95 (37.5) 45 (37.5) 50 (37.6)
Insulin pumps 151 (59.7) 72 (60) 79 (59.3)
Data are means  SD and n (%). *The number of months from the diagnosis until the ﬁrst registered A1C value multiplied by A1C units above the upper normal
reference value (6.4%) of the ﬁrst registered value, plus the number of months from the ﬁrst to second registration multiplied by A1C units above the upper normal
reference value of the second registered value, and so on until the time of cIMT analysis.
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type 1 diabetes (7). However, this ten-
dencywasnotobservedamongtheyoung
patients in this study.
Thediabeticpatientsinthisstudyhad
higher BMI than the control subjects.
Children and adolescents with type 1 di-
abetes have been found to be more prone
to a high BMI than their nondiabetic
peers, especially adolescent girls and
those using intensive insulin treatments.
This is often explained by overinsuliniza-
tion during intensive insulin treatment,
frequent hypoglycemic episodes treated
by additional food intake, and nutritional
liberation leading to increased energy in-
take (23).
No association between conventional
CVD risk factors, such as blood pressure
and LDL cholesterol, and vascular struc-
ture and function, such as cIMT and/or
distensibility, compliance, and wall
stress, could be detected in this study.
However, the blood pressure and choles-
terolvalueswerewithinthenormalrange,
the patients were young with short dis-
ease duration, and the changes in cIMT
were small, which might explain why no
associations between conventional CVD
risk factors and vascular structure and
function could be found.
A direct association between cIMT
and age was not found in this study. Al-
though cIMT increases with age in adults,
this relationship has not been as clearly
demonstrated in children and adoles-
cents. Our results are in concordance
with results from Sass et al. (24) who
found no correlation between age and
cIMT in a group of 160 normal control
subjects 10–18 years old.
Chronic glycemic exposure (the de-
gree and duration of hyperglycemia) has
been associated with macrovascular com-
plications and increased cardiovascular
risk in adult diabetic patients (2,8,9). In
the present study no association between
cIMT and glycemic control (A1C at the
time of study) or glycemic burden was
observed. However, the changes in IMT
were small, the observational period was
short and the cumulative glycemic expo-
sure was low. Orchard et al. (16) found
that it took 1,000 A1 months exposure
ofonaverageforamicrovascularcompli-
cation to develop compared with an aver-
age of 119 A1 months of exposure in this
study. Furthermore, the studies showing
association between glycemic control and
degree of atherosclerosis, using image
techniques, have done so after a long ob-
servational period (2,7–9).
An association between cIMT and age
of diabetes onset was observed in this
study. The mechanism behind this is not
clear. It is possible that age might some-
how inﬂuence the metabolic effects of di-
abetesonthevasculatureandthatanearly
manifestation of the disease may result in
earlyonsetandacceleratedprogressionof
atherosclerosis. In any case, these results
do not support the general impression
that the early prepubertal years of diabe-
tes do not affect the development of vas-
cular complications.
The results from this study indicate
that children and adolescents with type 1
diabetes have more atherosclerotic
changes than healthy control subjects,
even with short disease duration and de-
spite intensive insulin treatment and fair
metabolic control, and these changes are
most prominent among boys. This is a
baseline examination in a longitudinal
prospective study, and though the results
indicate more advanced atherosclerotic
development in the diabetic group, it is
reassuring that the changes are small in
this group of young patients at this early
stage of the disease.
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